IO Biotech, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that IO Biotech, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($95.49M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($86.08M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($71.46M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($67.88M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($12.04M) | Mar 31, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($95.18M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($91.44M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($71.42M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($41.23M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($10.15M) | Mar 31, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $71.48M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $67.83M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $46.99M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $30.15M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $8.46M | Mar 31, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($82.35M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($71.74M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($59.73M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($40.65M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($9.96M) | Mar 31, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $44.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $323.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $690.0K | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $153.0K | Mar 14, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $67.70M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $150.72M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $151.81M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $222.29M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $5.65M | Mar 31, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $20.68M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $17.56M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.95M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $10.36M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $3.05M | Mar 31, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $47.02M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $133.16M | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $138.85M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $211.92M | Mar 5, 2024 |
| FY2022 | Dec 31, 2020 | ($35.30M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | ($23.53M) | Mar 31, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($359.31M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($263.82M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($177.74M) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | ($106.28M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($38.40M) | Mar 31, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $60.03M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $143.19M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $142.59M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | $211.53M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $3.41M | Mar 31, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (1) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (17) | Mar 14, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | (1) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | (17) | Mar 14, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 65.88M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 65.88M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 28.82M | Mar 5, 2024 |
| FY2022 | Dec 31, 2021 | 28.82M | Mar 14, 2023 |
| FY2024 | Nov 9, 2021 | 28.82M | Mar 31, 2025 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |